A proton pump inhibitor's effect on bone metabolism mediated by osteoclast action in old age: A prospective randomized study

Gut and Liver

Volumn 9, Issue 5, 2015, Pages 607-614

  Jo, Yunju ^a   Park, Eunkyoung ^a   Ahn, Sang Bong ^a   Jo, Young Kwan ^a   Son, Byungkwan ^a   Kim, Seong Hwan ^a   Park, Young Sook ^a   Kim, Hyo Jeong ^a  

^a Eulji General Hospital   (South Korea)

Author keywords

Bone metabolism; Hydrogen potassium ATPase; Osteoclasts; Osteoporosis; Proton pump inhibitors

Indexed keywords

CALCIUM; CREATININE; DEOXYPYRIDINOLINE; GASTRIN; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; OSTEOCALCIN; PANTOPRAZOLE; PARATHYROID HORMONE; PEPSINOGEN I; PEPSINOGEN II; REVAPRAZAN; AMINO ACID; PROTON PUMP INHIBITOR; PYRIMIDINONE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM BONE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PREDICTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENESCENCE; SOUTH KOREA; STOMACH ULCER; BLOOD; BONE; BONE REMODELING; DRUG EFFECTS; METABOLISM; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; URINE;

AGED; AMINO ACIDS; BONE AND BONES; BONE REMODELING; CALCIUM; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOCLASTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; PYRIMIDINONES; TETRAHYDROISOQUINOLINES;

EID: 84942080295     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl14135     Document Type: Article

References (32)

1. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19:25-35.
2. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326.
3. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953.
4. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-259.
5. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
6. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-959.
7. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol 1998;44:473-481.
8. Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998;22:569-573.
9. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-781.
10. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995;14:364-368.
11. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+, K (+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21-25.
12. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010;25:2786-2795.
13. Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop 2003;32:222-228.
14. Dhonukshe-Rutten RA, Lips M, De Jong N, et al. Vitamin B-12 status is associated with bone mineral content and bone mineral density in frail elderly women but not in men. J Nutr 2003;133:801-807.
15. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen crosslinking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-162.
16. McLean RR, Jacques PF, Selhub J, et al. Plasma B vitamins, homocysteine, and their relation with bone loss and hip fracture in elderly men and women. J Clin Endocrinol Metab 2008;93:2206-2212.
17. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-2049.
18. Gagnemo-Persson R, Håkanson R, Sundler F, Persson P. Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol 1994;29:493-497.
19. Gagnemo-Persson R, Samuelsson A, Hâkanson R, Persson P. Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int 1997;61:210-215.
20. Kim HK, Park SH, Cheung DY, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol 2010;25:1618-1625.
21. Li H, Chung SJ, Kim DC, Kim HS, Lee JW, Shim CK. The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1, 2, 3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. Drug Metab Dispos 2001;29:54-59.
22. Mori H, Tonai-Kachi H, Ochi Y, et al. N-(2-hydroxyethyl)-N, 2-dimethyl-8-{[(4R)-5-methyl-3, 4-dihydro-2H-chromen-4-yl]ami no}imidazo[1, 2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther 2009;328:671-679.
23. Kim YG, Jang BI, Kim TN. A matched case-control study of a novel acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection. Gut Liver 2010;4:25-30.
24. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
25. Fossmark R, Stunes AK, Petzold C, et al. Decreased bone mineral density and reduced bone quality in H (+)/K (+) ATPase betasubunit deficient mice. J Cell Biochem 2012;113:141-147.
26. Joo MK, Park JJ, Lee BJ, et al. The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats. Mol Med Rep 2013;7:1267-1272.
27. Kocsis I, Arató A, Bodánszky H, et al. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int 2002;71:129-132.
28. Sharara AI, El-Halabi MM, Ghaith OA, et al. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism 2013;62:518-526.
29. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84:13-19.
30. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984;73:640-647.
31. Nam YD, Jung MJ, Roh SW, Kim MS, Bae JW. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLoS One 2011;6:e22109.
32. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010;25:2205-2211.